Cargando…
Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
Background: The ESE-ENSAT guidelines on the management of adrenocortical carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion for or a...
Autores principales: | Terzolo, Massimo, Fassnacht, Martin, Perotti, Paola, Libe, Rossella, Lacroix, André, Kastelan, Darko, Haak, Harm Reinout, Arlt, Wiebke, Loli, Paola, Decoudier, Bénédicte, Lasolle, Helene, Bancos, Irina, Quinkler, Marcus, Villares Fragoso, Maria Candida Barisson, Canu, Letizia, Puglisi, Soraya, Kroiss, Matthias, Dusek, Tina, Bourdeau, Isabelle, Baudin, Eric, Berchialla, Paola, Beuschlein, Felix, Bertherat, Jerome Yves, Berruti, Alfredo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265733/ http://dx.doi.org/10.1210/jendso/bvab048.336 |
Ejemplares similares
-
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023) -
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021) -
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020) -
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019) -
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)